{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    6,
    7,
    20,
    25,
    26,
    34,
    41,
    45,
    47,
    48,
    49,
    50,
    52,
    54
  ],
  "modelUsed": "gemini-3-pro-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Screening Procedures Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3",
        "sectionTitle": "Schedule of Activities (SoA), Table 1",
        "pageNumber": 3,
        "description": "Reference to screening site procedures detailed in Section 8"
      },
      {
        "id": "ref_2",
        "name": "COVID-19 Vaccine Risk Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.5",
        "sectionTitle": "COVID-19 Vaccine Risk Assessment",
        "pageNumber": 21,
        "description": "Reference to specific consideration for COVID-19 vaccine risks"
      },
      {
        "id": "ref_3",
        "name": "Dose Modification Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.6",
        "sectionTitle": "Dose Modification",
        "pageNumber": 21,
        "description": "Reference for dose modification or discontinuation due to liver function, anemia, or leukopenia"
      },
      {
        "id": "ref_4",
        "name": "Adaptive Features Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 4",
        "sectionTitle": "Adaptive Protocol Features",
        "pageNumber": 26,
        "description": "Reference to adaptive features and their limits"
      },
      {
        "id": "ref_5",
        "name": "Dose Modification Criteria Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 7",
        "sectionTitle": "ALXN1840 Dose Modifications for Individual Participants",
        "pageNumber": 27,
        "description": "Reference to criteria for decreasing or interrupting dose"
      },
      {
        "id": "ref_6",
        "name": "Exclusion Criteria Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.2",
        "sectionTitle": "Exclusion Criteria",
        "pageNumber": 35,
        "description": "Reference regarding blood donation or blood loss restrictions"
      },
      {
        "id": "ref_7",
        "name": "Contraception Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.4",
        "sectionTitle": "Contraceptive Guidance and Collection of Pregnancy Information",
        "pageNumber": 35,
        "description": "Reference to appropriate contraceptive methods"
      },
      {
        "id": "ref_8",
        "name": "Inclusion Criteria Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.1",
        "sectionTitle": "Inclusion Criteria",
        "pageNumber": 35,
        "description": "Reference for start times for contraceptives"
      },
      {
        "id": "ref_9",
        "name": "Schedule of Activities Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3",
        "sectionTitle": "Schedule of Activities",
        "pageNumber": 42,
        "description": "Reference for data to be collected at discontinuation"
      },
      {
        "id": "ref_10",
        "name": "Lost to Follow-up Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.3",
        "sectionTitle": "Lost to Follow-up",
        "pageNumber": 48,
        "description": "Reference for definition of lost to follow-up"
      },
      {
        "id": "ref_11",
        "name": "Molybdenum Measurement Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.1.1",
        "sectionTitle": "Copper and Molybdenum Balance Measurements",
        "pageNumber": 50,
        "description": "Reference for details of molybdenum measured in food, drinks, urine, and feces"
      },
      {
        "id": "ref_12",
        "name": "Populations for Analysis Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 8",
        "sectionTitle": "Populations for Analysis",
        "pageNumber": 51,
        "description": "Reference to defined population sets"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; IB = Investigatorâ€™s Brochure; PK = pharmacokinetics; WD = Wilson disease.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 3: Potential Risks and Mitigation Strategy",
        "pageNumber": 21
      },
      {
        "id": "annot_2",
        "text": "Abbreviations: CRF = case report form; CRU = clinical research unit; EOS = End of Study; SoA = Schedule of Activities.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 5: Participant Lifestyle Considerations",
        "pageNumber": 35
      },
      {
        "id": "annot_3",
        "text": "Abbreviations: ICF = informed consent form; PD = pharmacodynamic; PK = pharmacokinetic.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 8: Populations for Analysis",
        "pageNumber": 51
      },
      {
        "id": "annot_4",
        "text": "Note: total molybdenum and PUF molybdenum concentration-time profiles on Day 28 after the last 15 mg ALXN1840 dose will be extrapolated to Day 29 (0-24 hr) and subtracted from the observed Day 29 concentration-time profiles after the first 30 mg",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "9.4.4 Pharmacokinetic, Pharmacodynamic, and Biomarker Analyses",
        "pageNumber": 53
      },
      {
        "id": "annot_5",
        "text": "This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 2001/20/EC... and 21 CFR part 312.30(b)",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Protocol Amendment Summary of Changes Table",
        "pageNumber": 3
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_current",
        "versionNumber": "3.1 (US)",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2022-03-18",
        "description": "Protocol Amendment 3.1 (US) clarifying study procedures for US sites",
        "amendmentNumber": "Amendment 3.1"
      },
      {
        "id": "ver_orig",
        "versionNumber": "1.0",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-05-12",
        "description": "Original Protocol",
        "amendmentNumber": "Original Protocol"
      },
      {
        "id": "ver_amd1",
        "versionNumber": "2.0",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-08-18",
        "description": "Amendment 1",
        "amendmentNumber": "Amendment 1"
      },
      {
        "id": "ver_amd2",
        "versionNumber": "3.0",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-03-19",
        "description": "Amendment 2",
        "amendmentNumber": "Amendment 2"
      },
      {
        "id": "ver_amd3",
        "versionNumber": "4.0",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-08-31",
        "description": "Amendment 3",
        "amendmentNumber": "Amendment 3"
      }
    ],
    "summary": {
      "referenceCount": 12,
      "annotationCount": 5,
      "versionCount": 5
    }
  }
}